What was studied?
This analysis followed 1,032 participants with obesity and prediabetes from SURMOUNT-1 through 176 weeks of assigned treatment and a subsequent off-treatment period.
What did the researchers report?
Fewer tirzepatide participants received a type 2 diabetes diagnosis than placebo participants during the studied period. Weight changes and adverse events were also tracked; gastrointestinal events predominated among treatment-related concerns.
What are the limits?
The finding describes progression during a defined follow-up, not permanent immunity from diabetes. It applies to the studied population and pharmaceutical intervention, not to all people or commercial research supplies.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.